Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemical study

Hannaneh Golshahi; Abbas Tavasoly; Annahita Rezaie; Mohammad Farhadi

doi:10.2478/bvip-2013-0100

.blurhash-client-img { display: none !important; }

Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemical study

Journal of Veterinary Research

Volume 57 (2013): Issue 4 (December 2013)

By: Hannaneh Golshahi, Abbas Tavasoly, Annahita Rezaie and Mohammad Farhadi

Open Access

|Dec 2013

Abstract

Immunohistochemical expression of urokinase plasminogen activator (uPA) was studied in 37 canine malignant mammary tumours to define the relationship between their histopathological type and grade. In 29 (78.4%) cases, expression of uPA by neoplastic cells was more than 10% and in 34 samples (91.9%) uPA expression by stromal cells (fibroblasts) was more than 10%. The uPA was expressed in epithelial and myoepithelial cells of carcinomas and carcinosarcomas and mesenchymal population of carcinosarcoma, chondrosarcoma, and carcinomas arising in benign tumours. The intensity and percentage of expression of uPA by stromal cells was associated with their histological grade (P < 0.05). However, no significant relationship was detected between uPA expression by neoplastic cells (epithelial, myoepithelial, and mesenchymal cell) and histological grade. Increased expression of uPA by tumour stroma was associated with poor prognostic factors. Stromal expression of uPA could be a prognostic indicator for canine mammary tumours.

References

1. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J.: The urokinase type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72, 1-22.10.1002/(SICI)1097-0215(19970703)72:1<;1::AID-IJC1>3.0.CO;2-Z
Search in Google Scholar
2. Angenete E., Langenskiöld M., Palmgren I., Falk P., Öresland T., Ivarsson M.L.: uPA and PAI-1 in rectal cancer - relationship to radiotherapy and clinical outcome. J Surg Res 2009, 153, 46-53.10.1016/j.jss.2008.02.043
Search in Google Scholar
3. Bailey T.R., Paulsen D.B., Sehgal I., Hosgood G.: Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs. Am J Vet Res 2006, 67, 1628-1634.10.2460/ajvr.67.9.1628
Search in Google Scholar
4. Borgfeldt C., Casslen B., Liu C.L., Hansson S., Lecander I., Astedt B.: High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 1998, 79, 588-595.10.1002/(SICI)1097-0215(19981218)79:6<;588::AID-IJC6>3.0.CO;2-W
Search in Google Scholar
5. Blasi F., Carmeliet P.: uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002, 3, 932-943.10.1038/nrm977
Search in Google Scholar
6. Buo L., Meling G.I., Karlsrud T.S., Johansen H.T., Aasen A.O.: Antigen levels of urokinase plasminogen activator and its receptor at the tumour-host interface of colorectal adenocarcinomas are related to tumour aggressiveness. Hum Path 1995, 26, 1133-1138.10.1016/0046-8177(95)90276-7
Search in Google Scholar
7. Carmeliet P., Jain R.K.: Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.10.1038/35025220
Search in Google Scholar
8. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C.: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368, 419-424.10.1038/368419a0
Search in Google Scholar
9. Damjanovich L., Turzo C., Adany R.: Factors involved in the plasminogen activation system in human breast tumours.Thromb Haemost 1994, 71, 684-691.10.1055/s-0038-1642505
Search in Google Scholar
10. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D.: Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumour pathology. Am J Pathol 2000, 157, 1219-1227.10.1016/S0002-9440(10)64637-8
Search in Google Scholar
11. Duffy M.J., Duggan C.: The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem 2004, 37, 541-548.10.1016/j.clinbiochem.2004.05.013
Search in Google Scholar
12. Elston C.W., Ellis I.O.: Assessment of histological grade. In: Systemic Pathology - The Breast, edited by C.W. Elston and I.O. Ellis, Churchill and Livingstone, London, 1998, pp. 365-384.
Search in Google Scholar
13. Guo Y., Higazi A.A.R., Arakelian A., Sachais B.S., Cines D., Goldfarb R.H., Jones T.R., Kwaan H., Mazar A.P., Rabbani S.A.: A peptide derived from the non receptor binding region of urokinase plasminogen activator (uPA) inhibits tumour progression and angiogenesis and induces tumour cell death invivo. FASEB J 2000, 14, 1400-1410.10.1096/fasebj.14.10.1400
Search in Google Scholar
14. Han B., Nakamura M., Zhou G., Ishii A., Nakamura A., Bai Y., Mori I., Kakudo K.: Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol 2006, 28, 807-814.10.3892/ijo.28.4.807
Search in Google Scholar
15. Han B., Nakamura M., Mori I., Nakamura Y., Kakudo K.: Urokinase-type plasminogen activator system and breast cancer. Oncol Rep 2005, 14, 105-112.
Search in Google Scholar
16. Harbeck N., Kates R.E., Schmitt M., Gauger K., Kiechle M., Janicke F.: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Canc 2004, 5, 348-352.10.3816/CBC.2004.n.040
Search in Google Scholar
17. Hildenbrand R., Schaaf A., Dorn-Beineke A., Allgayer H., Sütterlin M., Marx A., Stroebel P.: Tumour stroma is the predominant uPA, uPAR, PAI-1expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009, 24, 869-877.
Search in Google Scholar
18. Hundsdorfer B., Zeilhofer H.F., Bock K.P., Dettmar P., Schmitt M., Kolki A., Pautke C., Horch H.H.: Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Cranio Maxill Surg 2005, 33, 191-196.10.1016/j.jcms.2004.12.005
Search in Google Scholar
19. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G.: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.10.1016/0092-8674(91)90642-C
Search in Google Scholar
20. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Fernö M., Eppenberger-Castori S., Sweep C.G., Ulm K., Peyrat J.P., Martin P.M., Magdelenat H., Brünner N., Duggan C., Lisboa B.W., Bendahl P.O., Quillien V., Daver A., Ricolleau G., Meijervan Gelder M.E., Manders P., Fiets W.E., Blankenstein M.A., Broët P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L.V., Klijn J.G., O'Higgins N., Eppenberger U., Jänicke F., Schmitt M., Foekens J.A.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94, 116-128.
Search in Google Scholar
21. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P.: Histological classification of the mammary tumours of the dog and the cat. In: World Health Organization InternationalHistological Classification of Tumours of Domestic Animals, edited by F.I. Shulman, Armed Forces Institute of Pathology, Washington DC, 1999, pp. 16-29
Search in Google Scholar
22. Nielsen B.S., Rank F., Illemann M., Lund L.R., Danø K.: Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007, 120, 2086-2095.10.1002/ijc.2234017290405
Search in Google Scholar
23. Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Danø, K.: Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001, 81, 1485-1501.10.1038/labinvest.378036311706057
Search in Google Scholar
24. Reuning U., Magdolen V., Hapke S., Schmitt M.: Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem 2003, 384, 1119-1131.10.1515/BC.2003.12512974381
Search in Google Scholar
25. Santos A.A., Lopes C.C., Ribeiro J.R., Martins L.R., Santos J.C., Amorim I.F., Gärtner F., Matos A.J.: Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study. BMC Vet Res 2013, 9, doi: 10.1186/1746-6148-9-1.10.1186/1746-6148-9-1354231223289974
Search in Google Scholar
26. Santos A., Lopes C., Marques R.M., Amorim I., Ribeiro J., Frias C., Vicente C., Gärtner F., Matos A.: Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet J 2011, 189, 43-48.10.1016/j.tvjl.2010.05.023
Search in Google Scholar
27. Schmitt M., Wilhelm O.G., Reuning U., Krüger A., Harbeck N., Lengyel E., Graeff H., Gänsbacher B., Kessler H., Bürgle M., Stürzebecher J., Sperl S., Magdolen V.: The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinolysis Proteol 2000, 14, 114-132.10.1054/fipr.2000.0079
Search in Google Scholar
28. Schneider J., Pollan M., Tejerina A., Sanchez J., Lucas A.R.: Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone- receptor-positive early breast cancer. Br J Cancer 2003, 88, 96-101.10.1038/sj.bjc.6600656
Search in Google Scholar
29. Ulisse S., Baldini E., Sorrenti S., D’Armiento M.: The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targ 2009, 9, 32-71.10.2174/156800909787314002
Search in Google Scholar
30. Wang Y.: The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001, 21, 146-170. 10.1002/1098-1128(200103)21:2<;146::AID-MED1004>3.0.CO;2-B
Search in Google Scholar

Articles in this issue

DOI: https://doi.org/10.2478/bvip-2013-0100 | Journal eISSN: 2450-8608

Journal RSS Feed

Language: English

Page range: 587 - 591

Published on: Dec 31, 2013

Published by: National Veterinary Research Institute in Pulawy

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

bitches,

mammary gland tumours,

urokinase plasminogen activator,

immunohistochemistry

Related subjects:

Life sciences,

Molecular biology,

Microbiology and virology,

Life sciences, other,

Medicine,

Veterinary medicine

© 2013 Hannaneh Golshahi, Abbas Tavasoly, Annahita Rezaie, Mohammad Farhadi, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons License.

Volume 57 (2013): Issue 4 (December 2013)